Results 151 to 160 of about 3,663 (172)

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

Atherosclerosis, 2016
Peter J H Jones, Maurizio Averna, Helen M Colhoun   +2 more
exaly  

Alirocumab/atorvastatin/pravastatin

Reactions Weekly, 2021
openaire   +1 more source

Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab

Annals of Pharmacotherapy, 2015
C Michael White
exaly  

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

New England Journal of Medicine, 2018
Gregory G Schwartz, Philippe Gabriel Steg, Michael Szarek   +2 more
exaly  

Alirocumab/evolocumab

Reactions Weekly, 2019
openaire   +1 more source

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

European Heart Journal, 2016
Patrick M Moriarty, Klaus G Parhofer, Marc-André Cornier   +2 more
exaly  

Alirocumab after Acute Coronary Syndrome

New England Journal of Medicine, 2019
Pignatelli, Pasquale, Camera, Marina, Violi, Francesco   +2 more
openaire   +7 more sources

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

Journal of Clinical Lipidology, 2017
G Kees Hovingh, Gisle Langslet, Marie T Baccara-Dinet   +2 more
exaly  

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years

Journal of Clinical Lipidology, 2017
Helen M Colhoun, William J Sasiela, Jay M Edelberg   +2 more
exaly  

Alirocumab for Hyperlipidemia: Odyssey Phase Iii Clinical Trial Results and US Fda Approval Indications

Future Cardiology, 2016
Eli M Roth
exaly